Great Britain approves subcutaneous Tecentriq weeks ahead of expected US decision
Patients in Great Britain who take IV Tecentriq now have a quicker option.
The country’s regulatory authority has approved a subcutaneous version of atezolizumab, better known as Roche’s blockbuster immunotherapy Tecentriq. The new version takes just seven minutes to administer, as opposed to 30 to 60 minutes for the IV formulation, Roche announced on Tuesday.
The news comes weeks ahead of an expected decision in the US on Sept. 15, executives said on the company’s recent Q2 earnings call per an AlphaSense transcript. In Great Britain, Tecentriq SC’s label covers all the same indications as the IV formulation and will be available “in the coming weeks,” a spokesperson told Endpoints News. The EU’s regulatory authority is currently considering the drug’s use, including in Northern Ireland.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.